Pulmonary Arterial Hypertension Clinical Trials 2023

Pulmonary Arterial Hypertension Clinical Trials 2023

Pulmonary Arterial Hypertension research studies recruiting patients in 2023 need your help. Receive premium care & cutting edge treatments by enrolling in pulmonary arterial hypertension clinical trials today.

Trials for PAH Patients

Trials for PH Patients

Phase 3 Trials

Trials With No Placebo

Frequently Asked Questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the 'trial drug' — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
Is there any support for travel costs?
Many of the teams running clinical trials will cover the cost of transportation to-and-from their care center.
Will I know what medication I am taking?
This depends on the specific study. If you're worried about receiving a placebo, you can actively filter out these trials using our search.
How long do clinical trials last?
Some trials will only require a single visit, while others will continue until your disease returns. It's fairly common for a trial to last somewhere between 1 and 6 months.
Do you verify all the trials on your website?
All of the trials listed on Power have been formally registered with the US Food and Drug Administration. Beyond this, some trials on Power have been formally 'verified' if the team behind the trial has completed an additional level of verification with our team.
How quickly will I hear back from a clinical trial?
Sadly, this response time can take anywhere from 6 hours to 2 weeks. We're working hard to speed up how quickly you hear back — in general, verified trials respond to patients within a few days.

Introduction to pulmonary arterial hypertension

What are the top hospitals conducting pulmonary arterial hypertension research?

When it comes to cutting-edge clinical trials in the field of pulmonary arterial hypertension, several top hospitals are leading the way. In Saint Louis, Washington University School of Medicine is at the forefront with seven ongoing trials focused on this condition. This renowned institution is dedicated to pushing the boundaries of knowledge and treatment for pulmonary arterial hypertension. Similarly, Duke University Medical Center in Durham has also embarked on seven active clinical trials in pursuit of better therapies for this challenging disease. With a reputation for excellence in research and patient care, they strive to make significant advancements in understanding and managing pulmonary arterial hypertension.

In Kansas City, the University of Kansas Medical Center has six ongoing studies aimed at improving outcomes for patients with pulmonary arterial hypertension. They are committed to finding innovative solutions that can enhance quality of life and prolong survival rates among those affected by this rare condition. Meanwhile, Vanderbilt University Medical Center located in Nashville shares a similar dedication as they too conduct six active clinical trials specifically addressing pulmonary arterial hypertension. Their efforts contribute significantly to unraveling new insights into this complex disease.

Finally, The Ohio State University Wexner Medical Center located in Columbus rounds out our list with five currently ongoing clinical trials focusing on pulmonary arterial hypertension. Their commitment demonstrates their passion for advancing medical knowledge surrounding this condition while striving towards more effective treatments.

Though these hospitals have yet to complete any past trials specific to pulmonary arterial hypertension (PAH), their current endeavors send an encouraging message that researchers across multiple prestigious institutions are actively working towards improving outcomes for PAH patients worldwide through groundbreaking investigations

Which are the best cities for pulmonary arterial hypertension clinical trials?

When it comes to pulmonary arterial hypertension clinical trials, several cities have emerged as leading centers for research and development. Los Angeles, California leads the way with 29 active trials exploring treatments like Ralinepag, AV-101, and Treprostinil Inhalation Powder. Boston, Massachusetts closely follows with 23 ongoing studies focused on innovative approaches such as Ralinepag and Sotatercept. New york, New York also plays a significant role in advancing treatment options with 18 active trials investigating therapies like GB002 (seralutinib) and Macitentan 75 mg. Additionally, Cincinnati, Ohio and Houston, Texas both contribute to the field of pulmonary arterial hypertension research through their respective 15 active trials. These cities offer individuals living with this condition access to cutting-edge clinical trials that pave the way for advancements in care and provide hope for improved outcomes.

Which are the top treatments for pulmonary arterial hypertension being explored in clinical trials?

Pulmonary arterial hypertension (PAH) is a challenging condition, but ongoing clinical trials bring hope for new treatments. The top contenders in these trials include:

  • Selexipag: Being explored in 8 active PAH trials and has been listed since 2015.
  • Riociguat: Under investigation in 6 current studies for PAH, with its first listing dating back to 2007.
  • Macitentan: Engaged in 4 active PAH trials and has been part of the research landscape since 2009.

These cutting-edge therapies are paving the way towards improved management and outcomes for individuals living with pulmonary arterial hypertension.

What are the most recent clinical trials for pulmonary arterial hypertension?

Exciting advancements are being made in the field of pulmonary arterial hypertension (PAH) through recent clinical trials. One notable trial investigates the efficacy of hyperpolarized 129Xe, offering potential insights into new treatment approaches for PAH patients. Another study focuses on healthy volunteers to gain a better understanding of this condition and improve diagnostic techniques. Additionally, researchers are evaluating the use of Treprostinil Palmitil Inhalation Powder (TPIP) in both Phase 2 and Phase 3 trials, aiming to provide an innovative therapeutic option for individuals with PAH. Furthermore, investigations also extend to pediatric populations aged ≥1 to <18 years old as they strive to enhance care tailored specifically towards younger patients. Lastly, a promising Phase 3 trial explores the potential benefits of low-dose AV-101 for those living with PAH. These cutting-edge studies offer hope for improved treatments that can positively impact the lives of individuals affected by PAH.

What pulmonary arterial hypertension clinical trials were recently completed?

Several recent clinical trials have made significant progress in the field of pulmonary arterial hypertension, offering hope for patients with this challenging condition. Notably, a trial conducted by United Therapeutics Corporation investigating Ralinepag reached completion in December 2021. Another important study sponsored by Actelion Pharmaceuticals explored the efficacy of Macitentan and concluded in September 2021. Furthermore, Merck Sharp & Dohme Corp completed their trial evaluating Vericiguat as a potential treatment option for pulmonary arterial hypertension in May 2021. These advancements represent promising steps forward in improving outcomes and quality of life for individuals living with this debilitating disease.